Please wait while we load the requested 10-K report or click the link below:
Edwards Lifesciences Corporation
One Edwards Way · Irvine, CA USA · 92614
Phone: 949.250.2500 · Fax: 949.250.2525
FOR IMMEDIATE RELEASE
Media Contact: Sarah Huoh, 949-250-5070
Investor Contact: David K. Erickson, 949-250-6826
EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
· THV Performance Drives Fourth Quarter Sales Growth of 15%
· Full Year 2015 Non-GAAP EPS Guidance Raised to $4.00 to $4.30
IRVINE, Calif., February 3, 2015 Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended December 31, 2014 of $109.2 million, or $1.00 per diluted share, and non-GAAP1 net income of $116.5 million, or $1.06 per diluted share. Net income for the same period a year earlier was $75.1 million, or $0.68 per diluted share, and non-GAAP net income was $105.0 million, or $0.95 per diluted share.
Net sales for the quarter ended December 31, 2014 increased 15 percent to $618.0 million compared to the same period last year. Underlying2 sales grew 16 percent to $614.2 million. U.S. and international segment sales for the fourth quarter were $286.6 million and $331.4 million, respectively.
In 2014, we were pleased to introduce several innovative products that helped us maintain our strong global leadership position. We are particularly gratified to see the meaningful impact that our dedicated employees have in helping so many patients around the world, said Michael A. Mussallem, chairman and CEO. For the quarter, we experienced robust growth across all regions, which was again led by transcatheter heart valves sales that exceeded our expectations, most notably in Europe.
For the fourth quarter, the company reported Transcatheter Heart Valve Therapy sales (THV) of $267.5 million, a 46 percent growth rate over the fourth quarter last year. On an underlying basis, THV sales grew 38 percent. These results were driven by strong
The following information was filed by Edwards Lifesciences Corp (EW) on Tuesday, February 3, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Edwards Lifesciences Corp's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Edwards Lifesciences Corp.